All Insurance Covered
( Cashless / Reimbursement )
Liraglutide Injection for Weight Loss
Want to lose weight without any surgery? Then the Liraglutide injection might be an excellent option. It suppresses appetite and helps with weight loss. If you plan to take this medication, your doctor will often recommend certain changes, such as diet and exercise. These lifestyle modifications can help maximize the effects of the injection and support your weight loss goals.
Liraglutide: A Versatile Medication for Diabetes and Weight Management
Liraglutide is a highly effective medication that has transformed the management of Type 2 diabetes and chronic weight issues. As a glucagon-like peptide-1 (GLP-1) receptor agonist, it mimics the action of the GLP-1 hormone, which regulates blood sugar levels and promotes feelings of fullness. This dual mechanism makes liraglutide a powerful tool for both glycemic control and weight management. Marketed under various brand names, including original formulations and biosimilars, liraglutide offers patients multiple options tailored to their medical needs. Below, we explore the key brands and their specific uses.
Neat & Clean Rooms
Spotlessly clean, profoundly caring. Our hospital ensures a pristine environment for your well-being
Modern Equiments
Our hospital has advanced technology gadgets and the best equipment in every field.
City Centre Location
Conveniently located at the heart of the city, our hospital offers easy access and exceptional care in a prime city center location
Victoza: The Pioneer for Type 2 Diabetes Management
Victoza, developed by Novo Nordisk, is the original brand name for liraglutide. It is primarily approved for managing Type 2 diabetes in adults and, in some cases, children aged 10 and older. Victoza works by stimulating insulin release when blood sugar levels are high, slowing gastric emptying, and reducing glucagon secretion, which collectively help maintain stable blood glucose levels. Administered as a once-daily subcutaneous injection, Victoza has been a cornerstone in diabetes care, often used alongside diet and exercise to improve glycemic control. It also offers cardiovascular benefits, reducing the risk of major adverse cardiovascular events in patients with Type 2 diabetes and high cardiovascular risk.
Saxenda: A Higher-Dose Solution for Weight Management
Also developed by Novo Nordisk, Saxenda is a higher-dose formulation of liraglutide specifically designed for chronic weight management. Approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities, Saxenda helps patients achieve and maintain weight loss when combined with a reduced-calorie diet and increased physical activity. By enhancing satiety and reducing appetite, Saxenda supports sustainable weight loss. Like Victoza, it is administered via a daily subcutaneous injection, but at a higher dose to target weight management effectively. According to the Cleveland Clinic, Saxenda is not intended for Type 2 diabetes treatment, though it shares the same active ingredient as Victoza.
Biosimilars: Expanding Access to Liraglutide
In addition to the original formulations by Novo Nordisk, several biosimilars have emerged, offering cost-effective alternatives while maintaining comparable efficacy and safety. Biosimilars are highly similar to the reference product (Victoza or Saxenda) and undergo rigorous testing to ensure therapeutic equivalence. Below are some notable biosimilars available in the market:
- Lirafit: Launched by Glenmark Pharmaceuticals, Lirafit is a biosimilar version of liraglutide designed to provide an affordable option for patients managing Type 2 diabetes. It mirrors the pharmacological profile of Victoza, offering a reliable alternative for glycemic control.
- Erly: Developed by Eris Lifesciences, Erly is another biosimilar of liraglutide, primarily targeted for Type 2 diabetes management. It provides a cost-effective solution for patients seeking to control blood sugar levels effectively.
- Gliptoza: Also from Eris Lifesciences, Gliptoza is a liraglutide biosimilar that expands treatment options for Type 2 diabetes. Its introduction reflects the growing demand for accessible diabetes therapies.
- Lyrato: Another offering from Eris Lifesciences, Lyrato is a biosimilar designed to deliver the same benefits as Victoza for patients with Type 2 diabetes, ensuring broader access to this critical medication.
How Liraglutide Works
Liraglutide’s mechanism of action is rooted in its ability to mimic GLP-1, a hormone that plays a key role in glucose metabolism and appetite regulation. It enhances insulin secretion in a glucose-dependent manner, meaning it activates only when blood sugar levels are elevated, reducing the risk of hypoglycemia. Additionally, liraglutide slows gastric emptying, which helps control post-meal blood sugar spikes and promotes a feeling of fullness. For weight management, as seen with Saxenda, this appetite-suppressing effect is particularly beneficial, helping patients adhere to a reduced-calorie diet.
Benefits and Considerations
Liraglutide, whether as Victoza, Saxenda, or a biosimilar, offers significant benefits:
- Glycemic Control: For Type 2 diabetes patients, it effectively lowers blood sugar levels and reduces HbA1c.
- Weight Loss: Saxenda supports meaningful weight reduction, improving obesity-related health conditions.
- Cardiovascular Health: Victoza has demonstrated cardiovascular benefits, making it a valuable option for patients with heart disease.
- Accessibility: Biosimilars like Lirafit, Erly, Gliptoza, and Lyrato make liraglutide more affordable, increasing access for patients worldwide.
